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As part of a programme of synthesizing and investigating the biological
properties of new fluoroquinolone antibacterials and their targeting of
topoisomerase IV from Streptococcus pneumoniae, we have solved the X-ray struc-
ture of the complexes of two new 7,8-bridged fluoroquinolones (with restricted
C7 group rotation favouring tight binding) in complex with the topoisomerase
IV from S. pneumoniae and an 18-base-pair DNA binding site—the E-site—
found by our DNA mapping studies to bind drug strongly in the presence of
topoisomerase IV (Leo et al. 2005 J. Biol. Chem. 280, 14 252–14 263, doi:10.
1074/jbc.M500156200). Although the degree of antibiotic resistance towards
fluoroquinolones is much lower than that of b-lactams and a range of ribo-
some-bound antibiotics, there is a pressing need to increase the diversity of
members of this successful clinically used class of drugs. The quinolone
moiety of the new 7,8-bridged agents ACHN-245 and ACHN-454 binds simi-
larly to that of clinafloxocin, levofloxacin, moxifloxacin and trovofloxacin but
the cyclic scaffold offers the possibility of chemical modification to produce
interactions with other topoisomerase residues at the active site.1. Introduction
Quinolone agents, which target type II topoisomerases in Gram-negative and
Gram-positive bacteria, are very important drugs in our armoury for the treat-
ment of serious microbial infections and for which there is increasing resistance
to b-lactam antibiotics. Quinolone drugs are not exempt from resistance, but
the levels of resistance exhibited by this class are at present lower than those for
b-lactam-based antibiotics and macrolides (statistics from Canadian Bacterial
Surveillance, 2009 [1]). Hence, there is a need to develop effective rationally
designed new pharmaceuticals of this class in order to bypass resistance
mutations. We have developed 7,8-bridged fluoroquinolones with the aim that
the restrictedmovement of the C7 group should favour tight binding. Quinolones
act on type II topoisomerase–DNA complexes to prevent strand passage of the
T-segment through the cleaved G-gate in the topoisomerase cycle [2]. When not
interrupted by drug interaction, this cycle starts with the reversible binding
(through the catalytic tyrosines) of the G-segment DNA to the G-gate consisting
of the TOPRIM andWHD domains of the core complex of the type II topoisome-
rase (figure 1). Capture of a transported T-segment DNA duplex by closure of the
N-gate ATPase domains allows strand passage through the double-stranded
break in the G-gate. Religation of the cleaved G-DNA segment and exit of the
G-segment
T-segment
N-gate
+ATP–ADP
4
1
2
3
C-gate
Figure 1. Schematic representation of the catalytic cycle of type II topoi-
somerases. ParC N-terminal domain (ParC55) is in grey, ParC C-terminal
b-pinwheel domain is in silver, ParE N-terminal ATPase domain is in red,
ParE C-terminal domain (ParE30) is in yellow, G-gate DNA is in green, trans-
ported (T) segment DNA is in purple. Bound ATP is indicated by pink circles in
the ATPase domains (reproduced with permission from fig. 1 of [3]).
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of one DNA through the other, and after ATP hydrolysis,
the enzyme resets for another cycle (figure 1). Quinolones
trap the covalent enzyme–DNA cleavage complex, preventing
DNA resealing and triggering cell death.
In prokaryotes, DNA topology is controlled by two type II
topoisomerase paralogues, topo IV (a tetramer with subunits
ParE2ParC2) and gyrase (a tetramer with subunits GyrA2-
GyrB2). The former mediates decatenation of replicated DNA
molecules and the latter regulates the overall level of DNA
supercoiling within the cell, which is perturbed by poly-
merases, helicases and other enzymes involved in replication,
transcription and recombination [2–14]. The elucidation of
the structures of topoisomerase II–drug–DNA complexes at
a resolution of 3.5 A˚ and above by ourselves [15–17] and
other workers in the field has meant that there is now a large
number of structures deposited with the PDB and a body of
knowledge of how a wide range of quinolone and other
drugs semi-intercalate into the DNA. How members of the
spiropyrimidinetrione compounds [18–20] and also how qui-
nazolinedione compounds [16,21] make contact with the
DNA bases and surrounding amino acids residues of their
topoisomerase IIA binding sites has been revealed [21–26].
Recent findings of Chan et al. show how the spiropyrimidine-
trione analogues and etoposide bind differently in the
hemi-intercalated binding site in the gyrase complex [23]. We
[16,27] and more recently other groups [21,28] have investi-
gated quinazolinediones, a class of antimicrobials that bind
through different side-chain interactions to quinolones and
select different gyrase and topoisomerase IV mutations in the
potential binding volume. Apparently minimal changes in
drug structure lead to a lack of cross-resistance with quino-
lones, an encouraging outcome that can be rationalized
structurally and potentially optimized for drug development.
A number of Gram-positive and Gram-negative pathogens
have been identified by the Centers for Disease Control, USA as
serious antimicrobial resistance threats, of which Streptococcus
pneumoniae is amajormedical concern. Streptococcus pneumoniae
is a Gram-positive bacterium and an important humanpathogen that causes a range of infections, including pulmon-
ary pneumonia, meningitis and otitis. Certain strains have
developed resistance to beta-lactams and erythromycin. As
part of our ongoing structural and biochemical studies aimed
at new topoisomerase-targeting therapeutics, we have focused
on topoisomerase IV–DNA complexes with ACHN-245 and
ACHN-454, two novel 7,8-bridged fluoroquinolones developed
and produced by Achaogen (figure 2c). For comparison,
figure 2 also shows structures of levofloxacin andmoxifloxacin,
two clinically important anti-pneumococcal fluoroquinolones,
and of the potent investigational quinolones clinafloxacin and
trovafloxacin. The new compounds are similar to clinafloxacin
in having cyclopropyl and 3-aminopyrroin-1-yl groups at the
respective 1- and 7-positions of the quinolone ring (figure 2).
However, they differ in having a heptacyclic ring system
formed between the quinolone 8-position and the 2-position
of the 3-aminopyrrolidin-1-yl substituent at position 7; this
seven-membered ring contains a double bond in ACHN-245
and a cyclic ether in ACHN-454. Levofloxacin has, by contrast,
a hexacyclic ring system between positions 1 and 8 of the quino-
lone (figure 2). The attraction of incorporating these bridging
ring systems is that they constrain rotation and provide a
scaffold for drug engineering, two features that potentially
increase binding affinity and selectivity. Here, we describe
the enzyme inhibitory and microbiological activities of the
compounds. Moreover, we report the structures of the topoi-
somerase IV–DNA cleavage complexes with ACHN-245 and
ACHN-454 at 3.43 and 3.24 A˚ resolution, respectively.
As in previous structures, we have made use of a DNA
duplex corresponding to the E-site, which we originally ident-
ified as an S. pneumoniae chromosomal DNA sequence that is
strongly cleaved by S. pneunomiae topo IV (and gyrase) in the
presence of a variety of different fluoroquinolones [29,30].
This property makes it an ideal DNA partner for crystallo-
graphic work on new quinolones. In contrast with the
fluoroquinolone complexes previously published by our
group, the E-site DNA oligomers used in this study were
changed from 34mers to 18mers (figure 2b), as part of an
optimization of experimental conditions which has yielded
reliable crystallization and structure solution of DNA cleavage
complexes. The shorter DNA substrate also produced a change
in the crystal space group from the previously reported P32 to
P3121 and has allowed higher-resolution structures of the com-
plexes with quinolones to be determined via co-crystallization
compared with those obtained by soaking. In turn, it has
yielded better-resolved electron density for the chelated
magnesium ions, which mediate key interactions among
protein, DNA and quinolones in the topoisomerase IV
cleavage complex [17,31].2. Material and methods
2.1. Cloning, expression and purification of
Streptococcus pneumoniae ParC and ParE proteins
The cloning, expression andpurification protocols forS. pneumo-
niae topoisomerase IV ParC, ParE, ParC55 and ParE30 proteins
have been described previously [16,32]. Quinolone-resistant
ParC S79F and quinazolinedione-resistant ParE E475A proteins
were overexpressed and purified as described [27,33,34].
topo IVS. pneumoniae
ParE30 ParC55
ParC (93K)
Hx6
ParE (72K)
N-terminal his-tag
ATP
trovafloxacinmoxifloxacin
levofloxacinclinafloxacin
ACHN-454ACHN-245
E-site sequence (18mer)
1 404
TOPRIM
Y1181647
598 31 55
WHD ‘tower’ CTD
235–327 C-gate 488
135 356–430 823
(b)
(a)
(c)
Figure 2. (a) Domain composition of the cleavage complexes of topoisomerase IV from Streptococcus pneumoniae (top) relative to the full-length proteins ParC and
ParE (bottom). (b) E-site 18mer DNA sequence; cleavage positions indicated by arrows, 4 bp overhang is highlighted in red. (c) Chemical structures of the Achaogen
quinolones used in the complexes, ACHN-245 and ACHN-454; chemical structures of the fluoroquinolones clinafloxacin, levofloxacin, moxifloxacin and trovafloxacin,
with their respective numbering schemes.
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In order to form the S. pneumoniae cleavage complex, E-site
18mer DNA oligomers (5’-CATGAATGACTATGCACG-3’,
5’-CGTGCATAGTCATTCATG-3’) were synthesized by
solid-phase phosphoramidite chemistry and doubly HPLC
purified by Metabion, Munich. The lyophilized DNAoligomers were reconstituted in the annealing buffer (20 mM
Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM b-mercaptoethanol,
0.05% NaN3), mixed in 1 : 1 molar ratio, heated to 958C and
then allowed to cool slowly to 48C over a period of 48 h in a
Dewar (sealed thermos flask). Macromolecule information is
provided in table 1.
Table 1. Macromolecule production information. Engineered tags and mutations are underlined.
source organism Streptococcus pneumoniae (isolate 7785, St. George’s Hospital; [34])
expression vector pET19b (N-terminal His10), pET29a (C-terminal His6)
expression host E.coli BL21(lDE3) pLysS
complete amino acid sequence of the recombinant protein ParC55:
MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSN
TFDKSYRKSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHG
NNGSMDGDPPAAMRYTEARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTV
LPAAFPNLLVNGSTGISAGYATDIPPHNLAEVIDAAVYMIDHPTAKIDKLMEF
LPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRSKTEIEKLKGGKEQIVITEIPYE
INKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAIELKKDANTELVLNY
LFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILARSRFDKEKA
EKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIVTLQ
LYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKF
ATPRLSSLEDTAKALEHHHHHH
ParE30:
MGHHHHHHHHHHSSGHIDDDDKHMKNKKDKGLLSGKLTPAQSKNPAKNEL
YLVEGDSAGGSAKQGRDRKFQAILPLRGKVINTAKAKMADILKNEEINTMIY
TIGAGVGADFSIEDANYDKIIIMTDADTDGAHIQTLLLTFFYRYMRPLVEAGH
VYIALPPLYKMSKGKGKKEEVAYAWTDGELEELRKQFGKGATLQRYKGLG
EMNADQLWETTMNPETRTLIRVTIEDLARAERRVNVLMGDKVEPRRKWIED
NVKFTLEEATVF
E-site DNA1
5’- CATGAATGACTATGCACG-3’
E-site DNA2
5’-CGTGCATAGTCATTCATG-3’
Table 2. Crystallization.
method vapour diffusion, sitting drop
plate type MRC Wilden 96 wells plate
temperature (K) 295
protein concentration 4–5 mg ml21
buffer composition of
protein solution
20 mM Tris, pH 7.5, 100 mM NaCl, 1 mM
b-mercaptoethanol, 0.05% NaN3
composition of
reservoir solution
50 mM Na cacodylate, 4–7% 2-propanol,
optimized mixture of salts (2% Tacsimate,
100–140 mM NaCl), pH 6.5
volume and
ratio of drop
600 nl : 400 nl protein : reservoir
volume of reservoir 80 ml
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ParE30 at an equimolar ratio in higher salt buffer (20 mM Tris-
HCl, pH 7.5, 200 mM NaCl, 1 mM b-mercaptoethanol, 0.05%
NaN3). The protein was then dialysed into lower salt buffer
(20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM b-mercap-
toethanol, 0.05% NaN3) and the cleavage complexes were
formed by mixing topo IV and E-site 18mer DNA at 1 : 1.2
molar ratio, respectively. Magnesium chloride and the drug
of interest were added to final concentrations of 10 mM and
1 mM, respectively. The complexes were allowed to form by
incubation at room temperature overnight.
Crystallization information is summarized in table 2.
Crystals of the cleavage complexes were obtained by
vapour diffusion using the sitting drop technique in
MRC Wilden crystallization plates. Drops were formed at
600 : 400 nl ratio for complex and precipitant solution,
respectively, using a Mosquito robot from TTP Labtech
(www.ttplabtech.com). The crystallization was performed
using a gradient grid varying pH from 6.0 to 7.0, NaCl
from 100 to 140 mM and isopropanol from 4 to 7%. The
rest of the crystallization cocktail was kept constant
(i.e. 50 mMNa cacodylate, 2% Tacsimate; Hampton Research)
[35]. Crystals of varying quality appeared stochastically
throughout the gradients used and no clear indication of
one strictly preferred crystallization condition was found
within the boundaries of the grid employed. Significant
prep-to-prep variation was also observed when differentbatches of the protein were used. Hence, it was found to be
essential to scan a range of conditions each time the crystal-
lization was performed. The best crystals were selected,
briefly placed into a cryoprotectant solution (50 mM Na caco-
dylate, pH 6.5, 2% Tacsimate [35], 62.5 mM KCl, 7.5 mM
MgCl2, 1 mM b-mercaptoethanol, 30% (v/v) MPD) and
then frozen directly in liquid nitrogen.
Table 3. Data collection and processing. Values for the outer shell are
given in parentheses.
ACHN-245 ACHN-454
diffraction source Diamond
beamline I02
Diamond
beamline I02
wavelength (A˚) 0.9795 0.9795
temperature (K) 100 100
detector ADSC quantum
315 CCD
ADSC quantum
315 CCD
crystal-detector
distance (mm)
391.900 391.926
rotation range per
image (8)
0.50 0.25
total rotation range (8) 82.5 114.0
exposure time per
image (s)
4.0 0.5
space group P3121 P3121
a, b, c (A˚) 157.83, 157.83,
210.71
157.86, 157.86,
210.78
a, b, g (8) 90, 90, 120 90, 90, 120
mosaicity (8) 0.167 0.107
resolution range (A˚) 41.819–3.43
(3.52–3.43)
41.828–3.24
(3.32–3.24)
total no. of reﬂections 206 644 337 161
no. of unique reﬂections 40 043 48 761
completeness (%) 97.1 (98.20) 99.9 (100.00)
redundancy 5.16 (5.22) 6.91 (7.13)
kI/s(I )l 14.38 (6.37)a 19.16 (5.91)a
Rr.i.m. (%)
b 13.587 (44.3) 8.76 (41.1)
overall B factor from
Wilson plot (A˚2)
54.11 71.30
aThe resolution cut-off used is based on the R-merge in the outer shell
being less than 50% and I/sig(I ) being above 1.5.
bEstimated Rr.i.m. ¼ Rmerge[N/(N 2 1)]1/2, where N ¼ data multiplicity.
Table 4. Structure solution and reﬁnement. Values for the outer shell are
given in parentheses.
ACHN-245 ACHN-454
resolution range (A˚) 41.819–3.430
(3.5157–3.4300)
41.828–3.240
(3.3061–3.2400)
completeness (%) 97.1 99.9
s cut-off F . 2.01s(F ) F . 2.00s(F )
no. of reﬂections,
working set
40 016 (2722) 48 732 (2680)
no. of reﬂections,
test set
2003 (134) 2446 (137)
ﬁnal Rcryst 0.154 (0.1825) 0.162 (0.2105)
ﬁnal Rfree 0.195 (0.2386) 0.185 (0.2145)
no. of non-H atoms
protein 10 388 10 339
nucleic acid 730 730
ion 6 6
ligand 54 54
water 24 14
total 11 202 11 143
r.m.s. deviations
bonds (A˚) 0.009 0.009
angles (8) 1.240 1.243
average B factors (A˚2)
protein 57.1 88.3
nucleic acid 65.6 99.2
ion 54.6 95.7
ligand 79.1 123.5
water 42.5 80.0
Ramachandran plot
most favoured (%) 92 90
allowed (%) 6 8
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Data collection and processing are summarized in table 3. Data
collection was performed using the GDE software available on
the I02 beamline at Diamond SLS, Oxfordshire. The programs
XDS and XSCALE [36,37] were used for data reduction. Struc-
ture solution and refinement are summarized in table 4. The
structures were solved with PHASER [38] as implemented in
the CCP4 suite [39]. Our 3K9F structure was used as the start-
ing protein model. Refinement was performed with PHENIX
[40,41] using multiple rounds of coordinate and temperature
factor refinement (employing TLS and secondary structure
geometry restraints). Manual model fitting and correction
was performed in WINCOOT [42,43].
Model qualitywas assessed using the in-built analysis tools
of WINCOOT (including geometry analysis and Ramachandran
plot) as well as the verification tools provided by the PDB.
Figures for this paper were generated using PYMOL [44],CHEMDRAW [45] and COREL DRAW (www.coreldraw.com). The
structure was verified using WINCOOT and PROCHECK [46].2.4. Drug susceptibilities and topoisomerase assays
Bacterial susceptibility to drugs was determined by the broth
microdilution assay following CLSI-recommended guidelines.
Briefly, approximately 104 CFU of the S. pneumoniae strains
were inoculated in a final volume of 100 ml cation-adjusted
Mueller–Hinton broth supplemented with lysed horse blood
and twofold dilutions of the test compounds in 96-well
plates. Plates were incubated at 358C for 20–24 h. The MIC is
the drug concentration at which no growth was seen when
tested under these conditions.
Methods for assaying DNA gyrase and topoisomerase IV
activity including DNA cleavage have been described pre-
viously [32]. Briefly, DNA cleavage assays were set-up
90°
Figure 3. Orthogonal side and top views of the cleavage complex in cartoon representation respectively; ParC55 is in pale blue, ParE30 is in green-cyan, DNA is in
red. Drug molecules are in yellow in van der Waals representation.
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length topo IV reconstituted by combining ParC (450 ng)
and ParE (1 mg), or topo IV core domain ParE30-ParC55
fusion protein (400 ng), were incubated with DNA. Reaction
buffer contained 40 mM Tris-HCl, pH 7.5, 6 mM MgCl2,
10 mM DTT, 200 mM potassium glutamate and 50 mg ml21
BSA in a final volume of 20 ml with or without drug included.
Samples were incubated at 378C for 1 h followed by addition
of 2 ml of 10% SDS to each reaction to induce DNA cleavage.
After addition of proteinase K to 200 mg ml21, incubation
was continued at 428C for 1 h to digest DNA-bound protein.
Sample loading dye (5 ml) was added to each tube and DNA
cleavage products were separated by gel electrophoresis in
1% agarose. DNA bands were stained with ethidium bromide
and photographed under UV illumination. CC25 is the drug
concentration used in the DNA cleavage assay that converted
25% of the supercoiled DNA substrate into linear DNA.3. Results and discussion
We have co-crystallized S. pneumoniae topoisomerase IV
ParC–ParE breakage-reunion domain (ParC55, residues 1–
490) and ParE TOPRIM domain (ParE30, residues 390–631)
with an 18 bp DNA duplex (the E-site) stabilized by the
novel drugs ACHN-245 and ACHN-454 synthesized by
Achaogen [47]. The X-ray crystal structures of the complexes
with ACHN-245 and ACHN-454 were determined at 3.43 and
3.24 A˚, respectively, showing a closed ParC55 dimer flanked
by two ParE30 monomers (figures 3–6). The macromolecular
structure of this tetrameric complex is similar to that found
for other S. pneumoniae topoisomerase–DNA–drug core com-
plexes that we have previously reported [15–17]. We note
that residues 6–30 of the N-terminal a-helix, a1 of the ParC
subunit embrace the ParE subunit, pulling the ParE subunits
close to either side of the ParC dimer (figure 3) [16]. This
interaction, absent from our original ParC55 dimer structure
[48,49], appears to be very important for ParC–ParE complex
stability as deletion of the a-1 arm resulted in loss of DNA
cleavage activity [48]. Figure 2a outlines the modular struc-
ture of the ParC and ParE proteins, mapping the positions
of the TOPRIM metal binding domain, WHD (the wingedhelix domain) [50] and the TOWER regions of the protein
subunits. This architecture has now been found in both topoi-
somerase IVs and gyrases from bacteria, and in topo IIa and
topo IIb from eukaryotes. The upper part of the topoisome-
rase complex consists of the E-subunit TOPRIM domain
formed of four parallel b-sheets and surrounding a-helices.
The WHD within the C-subunit together with the TOWER
forms the U-groove-shaped protein region into which the
G-gate DNA binds inducing a banana-shaped bend. The
lower C-gate region (figure 3a) forms the region of the struc-
ture through which the T-segment DNA is envisaged to exit
(see figure 1 illustrating the stages in the catalytic cycle) and is
formed of a pair of two long a-helices terminated by a span-
ning short a-helix. Dimerization of the C domains at this point
forms the 30 A˚ cavity, whichwill accommodate a B-DNAhelix.
The topoisomerase IV from S. pneumoniae is thought to follow
the generic topoisomerase catalytic cycle shown in figure 1
involving putative intermediates 1–4, for which we have con-
firmation of intermediate 1 from our recent structure of the full
complex (the holoenzyme less the CTD b-pinwheel domain)
with the ATPase domains in the open conformation [3]. More-
over, a closed state with dimerized ATPase domains has been
observed in a yeast topo II structure from Berger’s group [51].
The G-gate DNA for our S. pneumoniae complexes stabilized
by 7,8-bridgedquinolones is the 18 bp E-site sequence, our nota-
tion for a DNA site that we first found in cleavage mapping
studies of the S. pneumoniae chromosome [29,30]. It is clear
from the presence of covalent DNA–protein links to ParC
Y118 residues that the protein structures solved here (and earlier
[15,16]) represent quinolone-stabilized cleavage complexes
formed by turning over the topoisomerase IV tetramer bound
to DNA. Interestingly, the E-site DNA sequence has sub-
sequently been used in the successful co-crystallization of
quinolone–DNA cleavage complexes ofAcinetobacter baumannii
topoisomerase IV [31] and Mycobacterium tuberculosis DNA
gyrase [52], thoughwithout identification or reference to its ori-
gins in the S. pneumoniae system. It appears that the E-site is a
versatile DNA substrate that permits the crystallization and
structure solution of complexes formed with a variety of type
II topoisomerases and cleavage-enhancing drugs.
Within the S. pneumoniae topoisomerase IV complex, a
7,8-bridged quinolone is hemi-intercalated into each DNA
(e) ( f )
(b)(a) (c)
(d )
Figure 4. Detailed structural views of the binding sites for the quinolones ACHN-245 (a– c) and ACHN-454 (d– f ). (a,d ) Opposing views of the drug molecules with
the chelated magnesium ions and the electron density from the 2Fobs– Fcalc composite omit map contoured at the 1.5s level. (b,e) Opposing views of the drug-
binding site. ParC backbone is in blue, ParE backbone is in yellow, DNA backbone is in cyan, drug molecule is in red, magnesium ions are in purple, active site
tyrosine (Y118) and arginine (R117) are in orange, DNA bases and sugars are in silver, active site magnesium-coordinating residues are in purple, residues respon-
sible for drug resistance upon mutation are in red. (c,f ) Schematic representation of the coordination of the drug in the active site. Important distances and likely
hydrogen bonds are shown by dashed lines.
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(positions 21 and þ1 of the 4 bp staggered cut in the 18mer
DNA) (figures 3–6) as found now in many other Gram-
negative and Gram-positive topoisomerase IV and gyrasecomplexes. Figure 4a,d illustrates the electron density for the
bound drugs in two views related by a 1808 rotation show-
ing the bound magnesium ion (purple sphere) within the
electron density envelope coordinated between the carbonyl
D506 D506
D508 D508
ACHN-245
ACHN-454S79
D83 D83
–1
–1
+1 +1
+5 +5
+4 +4
E433
Y118
R117
Mg2+
E433 Y118
R117
Mg2+
Mg2+
S79
Mg2+
(b)(a)
Figure 5. Top view on to the DNA cleft stabilized by the quinolone drugs ACHN-245 (a) and ACHN-454 (b).The ParC backbone is in blue, the ParE backbone is in
yellow, DNA backbone is in cyan, drug molecule is in red, magnesium ions are in purple, active site tyrosine (Y118) and arginine (R117) are in orange, DNA bases
and sugars are in silver, active site magnesium-coordinating residues are in purple, ParC S79 and D83 residues responsible for quinolone resistance upon mutation
are in red.
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tion 3. How this magnesium ion makes further but longer
interactions, now of around 4 A˚ in length with the thymidine
base at position 1 and the ParC D83 side chain, is also shown
(figure 4b,c,e,f ). This is probably coordinated through a water
molecule whose density we do not see but is theoretically con-
firmed by placing waters in a hexacoordinated system around
the Mg2þ. These interactions are the same for both ACHN-245
and ACHN-454 (figure 4a–f). The carboxyl at quinolone pos-
ition 3, besides interacting with this magnesium ion, also
makes interactions with ParC S79 and R117; the lengths of
these interactions are similar for both drugs. Thus, the drug
molecules are in close register to ParC S79 and D83 residues,
two mutational hotspots to quinolone resistance [33,34,53,54].
The amino group on the 7-(3-aminopyrrolidin-1-yl) group
makes key interactions with a cluster of two glutamates and
an arginine (ParE E474, E475 and R456 in ParE) through a
single oxygen of the carboxyl groups of the glutamates and
themain chain carbonyl of R456 (figure 4b,c,e,f). The hydrogen
atoms of the cyclopropyl substituents are within a 4 A˚ range of
the two of the oxygens of the phosphotyrosine Y118. Note that
a second Mg2þ ion at each drug-binding site coordinated by
ParE E433, D506 and D508 interacts with the DNA phospho-
diester group between 21 and 22 (figure 4b,e) and, through
repositioning in the absence of drug, may be involved in
DNA strand breakage-reunion.
Figure 5 shows an edge-on view and illustrates how the
ACHN-245 and 454 drugs are hemi-intercalated into a
wedge-shaped binding pocket, forming p–p* stacking inter-
actions between the aromatic quinolone rings and the DNA
bases. In both cases, the cyclopropyl group on N-1 of the qui-
nolone is cocked out of the plane of the quinolone. Figure 5
presents the key disposition of the Mg2þ ions, with the
Mg2þ coordinated to the carbonyl and carboxyl of the drugtogether with S79 and D83 side chains, located behind as
part of an alpha helix. At the top left of figure 5a,b, the
second Mg2þ is coordinated to the catalytic cluster of E433,
D506, D508, a glutamate/aspartate triad which has been
found in many eukaryotic, archaeal and prokaryotic topoi-
somerases as well as in many recombinases, nucleases and
polymerases [55–59]. In figure 6 are shown two orthogonal
views of how the drugs are sandwiched between the bases
superposed with our highest resolution (2.9 A˚) structure of
the clinafloxacin cleavage complex. The stacking interactions
are very similar, but the cycloheptyl group of these Achaogen
compounds projects towards R456 and D435 (figure 6a,c;
figure 4c,f) and if modified could form a scaffold for substitu-
ents which could span towards these and other residues and
impart further contacts. The cyclogroup of the Achaogen com-
pounds projects towards the van der Waals cavity formed by
the sugars of the DNA about the semi-intercalation and the
only protein side chain making a close approach is E475
(figure 6a,c). In figure 6e,f are shown the superpositions of
the Achaogen compounds with clinafloxacin in the complex
3RAD where the 7-group is free to rotate in contrast with its
locked conformation in the Achaogen compounds.
The disposition of the quinolone drugs in the topoisome-
rase binding site is very similar to that of levofloxacin, and
clinafloxacin, and the ring structure gives hindered rotation
to the 7-(3-aminopyrrolidin-1-yl) moiety and maintains key
interactions with E474, E475 and R456. The disposition of the
cycloheptyl group shows how with further chemical elabor-
ation of this scaffold, further interactions with neighbouring
residues in the binding pocket may be formed.
Both antimicrobial susceptibility and enzyme-DNA
cleavage assays reveal the 7,8-bridged fluoroquinolones
ACHN-245 and ACHN-454 to be potent anti-pneumococcal
agents. Table 5 presents the MIC data for the two compounds
(e) ( f )
(b)(a)
(c) (d )
active site Ca r.m.s.d.: 0.283 A° active site Ca r.m.s.d.: 0.350 A°
Figure 6. Comparison of cleavage complexes formed by 7,8-bridged fluoroquinolones and by clinafloxacin, their non-bridged counterpart. (a,b) Orthogonal views of
the least-atom least-squares superposition of the ACHN-245 complex active site (4KPE) with that of the clinafloxacin complex (3RAD) determined at 3.35 A˚ res-
olution. (c,d ) Orthogonal views of the least-atom least-squares superposition of the ACHN-454 complex active site (4KPF) with that of the clinafloxacin complex
(3RAD). (e,f ) Superposition of ACHN-245 (from 4KPE) (e) and of ACHN-454 (from 4KPF) ( f ) in each case with clinafloxacin (from 3RAD).
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Na b 1.0 2.5
Levo Clina ACHN245 ACHN454
5.0 10 0.1 0.25 0.5 1.0 0.1 0.25 0.5 1.0 0.1 0.25 0.5 1.0 (mm)
L
S
Figure 7. 7,8-bridged fluoroquinolones are potent mediators of DNA cleavage by Streptococcus pneumoniae topoisomerase IV. Supercoiled plasmid pBR322 DNA
(400 ng) was incubated with S. pneumoniae ParE30-ParC55 fusion protein (400 ng) in the absence or presence of levofloxacin (Levo), clinafloxacin (Clina), or the 7,8-
bridged fluoroquinolones ACHN-245 and ACHN-454 at the indicated concentrations. After incubation at 378C, samples were treated with SDS and proteinase K to
remove covalently linked protein and the DNA products were examined by gel electrophoresis in 1% agarose, as described in the Material and methods. Lane a,
supercoiled pBR322 DNA; lane b, DNA plus topo IV protein (no drug); N, L and S denote nicked, linear and supercoiled pBR322, respectively.
Table 5. Anti-pneumococcal activity of 7,8-bridged quinolones ACHN-245 and ACHN-454.
strain
code source genotype
MIC (mg l21)
levo ﬂoxacin clinaﬂoxacin ACHN-245 ACHN-454
ASPN002 ATCC wild-type 1 0.06 0.03 0.06
ASPN009 ATCC wild-type 0.5 0.06 0.03 0.06
ASPN1010 clinical isolate, Mount Sinai
(Toronto, Canada)
gyrA(S81Y) 2 0.5 0.25 0.25
ASPN1011 clinical isolate, Mount Sinai
(Toronto, Canada)
gyrA(S81Y); parC(D83N) 8 0.5 0.5 0.5
ASPN1009 clinical isolate, Mount Sinai
(Toronto, Canada)
gyrA(E85K); parC(S79Y);
parE(I460V)
32 1 0.5 1
ASPN1027 clinical isolate, Mount Sinai
(Toronto, Canada)
gyrA(S81F), parC(S79F,
K137N)
32 2 1 1
rsob.royalsocietypublishing.org
Open
Biol.6:160157
10
 on October 27, 2016http://rsob.royalsocietypublishing.org/Downloaded from against quinolone-susceptible and quinolone-resistant
S. pneumoniae strains. For comparison, data are included for
levofloxacin, a widely used anti-pneumococcal quinolone,
and for clinafloxacin, the experimental 8-chlorofluoroquino-
lone that bears the same 3-aminopyrrolidin-1-yl group at
position 7 that is bridged to C-8 in the Achaogen compounds.
Against the two quinolone-susceptible ATCC reference strains,
the two ACHN compounds exhibited MICs of 0.03–
0.06 mg l21 which is comparable to or marginally better than
clinafloxacin (0.06 mg l21) and much lower than the MICs for
levofloxacin, typically 0.5–1 mg l21 (table 5). Clearly, chemical
bridging of the 7 and 8 positions in the ACHN compounds
does not compromise anti-pneumococcal activity.
Compared with wild-type strains, clinical isolates harbour-
ing double quinolone-resistance mutations in gyrase and
topoisomerase IV e.g. ParC79F and GyrA81F exhibited an
8–16-fold increase in MIC for ACHN-245 and ACHN-454 to
0.25–1 mg l21, similar to the clinafloxacin MICs (table 5 and
reported earlier in [60]). Thus, although quinolone-resistantstrains have elevated MICs for ACHN-245 and ACHN-454,
these MICs are very much lower than the typical levofloxacin
MIC values of 32 mg l21 (table 5). Evidently, as with clinaflox-
acin, the greater potency of the 7,8-bridged compounds
extends to quinolone-resistant strains.
In complementary biochemical experiments, we examined
drug-induced DNA cleavage mediated by purified wild-type
S. pneumoniae topoisomerase IV and by its ParC79F and
ParE475A mutants that exhibit resistance to quinolones
and to antibacterial quinazolinediones, respectively (figures 7
and 8) [27]. The trapping of a topoisomerase–DNA cleavage
complex is thought to be the seminal event in quinolone and
quinazolinedione action that underlies their cytotoxic action
[27]. In studies of the wild-type enzyme, we used the topo IV
core domain—a ParE30-ParC55 fusion protein—that carries
all the determinants necessary for DNA cleavage. The protein
was incubated with supercoiled pBR322 DNA in the absence
and presence of drug, and following addition of SDS and pro-
teinase K, the DNA products were separated and analysed by
Na b 80 160 320 2.5 5.0 10 20 40 2.5 5.0 10 20 40 2.5 5.0 10 20 40
Levo Clina ACHN245 ACHN454
Levo Clina ACHN245 ACHN454
(mm)
a b 2.5 5.0 10 20 0.5 1.0 2.5 5.0 0.5 1.0 2.5 5.0 0.5 1.0 2.5 5.0 (mm)
L
S
N
L
S
(b)
(a)
Figure 8. ACHN-245 and ACHN-454 promote DNA cleavage by fluoroquinolone-resistant (ParC79F) topoisomerase IV (a) and by dione-resistant (ParE475A) topoi-
somerase IV (b) from Streptococcus pneumoniae. Supercoiled plasmid pBR322 (400 ng) was incubated with full-length topo IV reconstituted from 450 ng ParC79F
and 1 mg ParE (a) and 450 ng ParC and 1 mg ParE475A (b). DNA cleavage was induced and DNA products were analysed as described in the figure 7 legend. Lanes
a, supercoiled pBR322; lanes b, DNA plus mutant topoisomerase IV enzyme and no drug.
Table 6. Comparison of drug potencies of ACHN245, ACHN454 with
levoﬂoxacin and clinaﬂoxacin in DNA cleavage assays mediated by
S. pneumoniae topo IV. Results were average of three independent experiments.
proteins
CC25 (mM)
a
levo clina ACHN245 ACHN454
ParE30-ParC55
(WT)
2.5–5 0.25–0.5 0.25–0.5 0.5
ParC79F/ParE 160–320 20 20 20–40
ParE475A/ParC 5–10 2.5 2.5 2.5
aCC25, the drug concentration resulting in 25% conversion of supercoiled
pBR322 DNA into the linear form.
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absence of drug, the core enzyme converted supercoiled
pBR322 into a ladder of relaxed DNA topoisomers (figure 7,
lanes a and b), a well-documented activity of this truncated
topoisomerase IV complex not seen for the full-length holoen-
zyme (figure 8) [32]. Inclusion of drug led to the formation of
linearDNA in a dose-dependent fashion (figure 7). Comparing
the CC25 values (the drug concentration that converted 25% of
the supercoiled DNA substrate to the linear form), it is clear
that the two 7,8-bridged quinolones exhibited a similar
potency to clinafloxacin, with CC25 of 0.25–0.5 mM, about
10-fold more active than levofloxacin (figure 7; table 6).
Using full-length topoisomerase IV complexeswithmutant
ParC or ParE subunits, we could investigate the roles of ParC
S79 and ParE E475 residues in drug action (figure 8). We
could show that DNA cleavage mediated by the 7,8-bridged
quinolones, levofloxacin and clinafloxacin was in each case
much less efficient for the topoisomerase IV S79F mutant,
with CC25 values 40–80-fold higher than seen with the wt
enzyme (figure 8a; table 6). However, topo IV with a ParE
475A mutation showed only a twofold increase in CC25 for
levofloxacin (reported previously in [61]), but a 10–20-fold
increase for clinafloxacin, ACHN245 and ACHN454
(figure 8b; table 6). These results indicate that both ParC S79
and ParE E475 residues play a role in binding clinafloxacin
and the 7,8-bridged quinolones (figures 4c,f and 6).
Previously, we showed that the dione-resistant ParE475A
topoisomerase IV exhibited a similar 10–20-fold increase in
the CC25 for PD 0305970 [27]. We note that the ParE 475A
mutation was selected with this quinazolinedione, which has
a 3-aminopyrrolidin-1-yl group at position 7 closely similar
to that present in clinafloxacin and the 7,8-bridged quinolones,
but absent from levofloxacin. In conclusion, it may be that thepresence of a 3-aminopyrroline side chain is a key factor in
determining quinolone and dione interactions with ParE, and
thereby the resistance profile. In any event, these biochemical
experiments with mutant topoisomerase enzymes begin to
map out potential drug–side chain interactions explored
by the 7,8-bridged quinolones and by levofloxacin, a 1,8-
bridged quinolone. It appears that the 7,8-bridging chemistry
in the ACHN compounds does not reduce potency and
suggests there is scope to explore further substitutions along
the C1, C7 and C8 side of the quinolone that may enhance
drug activity against resistant strains [61,62].
The ACHN-245 and ACHN-454 S. pneumoniae topoisome-
rase IV structures were deposited in the PDB with accession
codes 4KPE and 4KPF, respectively.
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